Targeting type I interferon (IFN) signalling in patients with RA with a high type I IFN gene signature

RMD Open. 2022 Oct;8(2):e002525. doi: 10.1136/rmdopen-2022-002525.

Authors

Thomas Karonitsch¹, Lusine Yeghiazaryan², Angelika Lackner³, Hans Peter Brezinsek³, Tanja A Stamm², Franz König², Daniel Aletaha⁴, Josef S Smolen⁴

Affiliations

¹ Division of Rheumatology, Medical University of Vienna, Wien, Austria thomas.karonitsch@meduniwien.ac.at.
² Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Wien, Austria.
³ Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria.
⁴ Division of Rheumatology, Medical University of Vienna, Wien, Austria.

No abstract available

Keywords: Arthritis, Rheumatoid; Biological Therapy; Therapeutics.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Arthritis, Rheumatoid* / genetics
Humans
Interferon Type I* / genetics
Signal Transduction
Tumor Necrosis Factor-alpha

Substances

Interferon Type I
Tumor Necrosis Factor-alpha